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ABSTRACT 
The fine specificities of vaccine-elicited B cell responses against complex 
proteins are not well understood, including those directed against the HIV-1 envelope 
glycoproteins (Env). Env is the only surface-exposed viral protein and hence a major 
vaccine target, in particular the conserved determinants of Env. It is now well 
appreciated that HIV-1 has evolved mechanisms to occlude conserved determinants of 
Env to limit antibody recognition of these sites. Such structural constraints are thought 
to contribute to the limited capacity of current Env immunogens to stimulate broadly 
neutralizing antibodies. Numerous strategies have been undertaken to improve the 
capacity of Env immunogens to stimulate effective antibody responses, but so far this 
has met with limited success. An improved understanding of basic B cell biology and 
how it relates to Env immunogenicity is therefore needed. 
The primary goal of this thesis was to ask a number of basic questions 
regarding vaccine-induced B cell responses using an antigen that is highly relevant to 
human health, HIV-1 Env. To accomplish this, we developed an optimized B cell 
ELISpot assay, which can be used to enumerate total Env-specific B cells, as well as B 
cells directed against different sub-determinants of Env. In paper I, we immunized 
mice with recombinant, soluble Env trimers and we demonstrate that the relative 
proportion of Env sub-specificities changes significantly in response to boosting, with a 
robust expansion of B cells recognizing the gp41 moiety of Env after the first boost and 
of those recognizing variable region 3 after the second boost. In paper II, we designed 
a system to investigate how B cell responses to different elements of the same antigen 
affect one another. Using this system we show that different specificities develop 
independently of each other, suggesting that there is no or limited competition between 
B cell populations recognizing distal epitopes of the same antigen during the 
development of the immune response.  
In paper III, we used computationally designed scaffold immunogens displaying 
a specific broad neutralization epitope of Env. We show that heterologous scaffold 
proteins could be used sequentially to boost B cell responses that were reactive with the 
target epitope, but that this regimen did not provide an advantage over the use of a 
single scaffold. In paper IV, we exploited recombinant B Lymphocyte Stimulating 
factor (BLyS) to modulate the naïve B cell repertoire prior to Env immunization. We 
show that a transient treatment with BLyS increased the peripheral naïve B cell pools 
and interestingly, qualitatively enhanced Env-specific responses as evidenced by 
improved neutralization of HIV-1. Our data suggests that BLyS-regulated processes 
can be targeted to favorably affect the quality of Env vaccine-elicited neutralizing 
antibody responses against HIV-1. 
Collectively, the findings presented in this thesis provide new insights into the 
development of B cell responses to protein-based vaccines, specifically to recombinant 
HIV-1 Env immunogens. This information may accelerate the design of improved Env-
based immunization regimens and may also be of more general use for the 
development of vaccines against highly variable, neutralization-resistant pathogens. 
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1 INTRODUCTION 
Neutralizing antibodies (Abs) are the correlate of protection for most vaccines in 
use today. Many vaccines also induce strong cytotoxic T cell responses, but their role in 
vaccine-induced protection against pathogens is less defined (1). Abs are produced by 
antibody secreting cells (ASCs), also called plasma cells (PCs), which are formed 
during infection or vaccination. Short-lived PCs can be found in the periphery, while 
long-lived PCs reside predominately in the bone marrow (BM) where they may persist 
for the lifetime of the individual. These PCs produce high affinity Abs, which are 
released into the bloodstream continuously providing first line defense against 
pathogens.   
Even though the development of vaccines is one of the most successful 
achievements in medical history and many potent vaccines against harmful pathogens 
exist, there are still no vaccines available against pathogens such as hepatitis C virus 
(HCV) causing hepatitis, Plasmodium falciparum causing malaria and human 
immunodeficiency virus type-1 (HIV-1) causing acquired immunodeficiency syndrome 
(AIDS). Due to a number of factors, such as the extremely high genetic variability of 
these pathogens and the risk for infection, conventional vaccine approaches based on 
inactivated or attenuated preparations are not viable. Instead, strategies based on 
subunit vaccines using antigens (Ags) that are known Ab targets are pursued in most 
instances. To increase the likelihood of developing successful vaccines, the 
immunogenic properties of relevant Ags must be studied in pre-clinical animal models. 
An improved understanding of the limitations of vaccine candidates that fail to elicit 
the desired immune response is necessary to guide the development of improved 
approaches. 
In the work presented here, we have used a well-characterized HIV-1 envelope 
glycoprotein (Env) as a model protein Ag to study the development of immunization-
elicited B cell responses in mice. Env is the only relevant target Ag for an Ab-based 
vaccine against HIV-1 as it is the only protein that is exposed on the outside of the virus 
particle. It has been shown that passive immunization of broadly neutralizing Env-
specific Abs elicited naturally in HIV-1 infected individuals, provides protection 
against challenge with chimeric HIV-SIV virus (SHIV) in non-human primates (2-7). 
Yet, no vaccine approach to date has successfully induced such Abs in healthy 
individuals. Understanding the limitations of existing vaccine candidates is a critical 
task on the path to develop an effective preventative vaccine against HIV-1. 
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2 OBJECTIVES 
The overall aim of the work presented in this thesis was to study basic questions in 
B cell biology to help understand the development of vaccine-elicited B cell responses 
against protein antigens. To accomplish this, we used the HIV-1 Env glycoprotein as a 
model antigen and analyzed Env-specific B cell responses at both cellular and 
serological levels in immunized mice. The objectives of these studies were two-fold: to 
advance our knowledge regarding the evolution of B cell responses to large protein 
antigens in general and to investigate novel immunization approaches that may 
accelerate the development of an antibody-based vaccine against HIV-1. 
  
The specific aims for the four individual papers were: 
 
Paper I:  To determine the evolution of total and epitope-specific B cell responses 
over time in Env-immunized mice using an optimized, differential B cell 
ELISpot assay.  
 
Paper II:  To investigate whether B cells that recognize distal epitopes on the same 
antigen compete with one another in response to antigen re-exposure in 
vivo (boosting).  
 
Paper III:  To investigate the capacity of computationally designed scaffold proteins, 
engrafted with a broadly neutralizing antibody epitope of Env, to re-elicit 
responses against this epitope. 
 
Paper IV:  To investigate whether modulation of the naïve B cell repertoire by 
exogenous BLyS treatment prior to immunization improves the outcome 
of Env vaccine-elicited B cell responses.   
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3 B CELL BIOLOGY 
3.1 B CELL EVOLUTION IN THE BONE MARROW 
3.1.1 Early B cell development 
As with all other blood cells, B cells originate from hematopoietic stem cells 
(HSCs) residing in the BM. B cell hematopoiesis is a gradual process that is defined by 
the expression and suppression of different key transcription factors and by DNA 
recombination events essential for the generating functional B cell receptors (BCRs) 
that consists of two immunoglobulin heavy chains (IgH) and two immunoglobulin light 
chains (IgL) (reviewed in (8-10)). HSCs differentiate via an early lymphoid progenitor 
(ELP) into a common lymphoid progenitor (CLP). During the late CLP stage 
recombination of the IgH gene begins and the cells begin to express the IL-7 receptor. 
Ligand binding to this receptor provides an important survival signal and promotes 
differentiation of CLP into pro-B cells (11). Expression of the transcription factor Pax5 
is required for the transition of late CLP into the early pro-B cell stage and its 
expression defines the commitment to the B cell lineage (12). IgH gene rearrangement 
is completed as the B cells enter the late pro-B cell phase. At this stage the cells have 
reached an important checkpoint since they are only allowed to mature further into pre-
B cells if they display a properly expressed IgH chain in association with the surrogate 
light-chain components VpreB and λ5 to form the pre-BCR complex. When this 
complex is expressed on the surface of the cells, they are positively selected for further 
maturation into pre-B cells, which allows for rearrangement of the IgL gene (13, 14). 
The developing cells pass through another checkpoint in which only B cells with 
properly paired BCRs showing no to low affinity for self epitopes are selected to exit 
the BM for further development in the periphery (reviewed in ((15))). Self-reactive B 
cells or B cells with poorly paired BCR may be given a second chance to express a 
BCR of another specificity through a process termed receptor editing (16-18). In this 
process, the IgL chain of the BCR is reconstructed until the BCR does not recognize 
self. Failure at this step leads to B cell apoptosis (19). It has been shown that the 
numbers of self-reactive and poly-reactive B cells are decreased significantly at this 
check-point (20). This process is in general terms referred to as central tolerance (21) 
and is the prevailing mechanism to explain how B cells are educated to discriminate 
self from non-self. 
 
3.1.2 VDJ recombination 
The concept that man can produce Abs against an infinite range of pathogens 
may be difficult to comprehend. However, the immune system is estimated to be 
capable of producing Abs with over 1016 unique Ag-specificities (reviewed in (22)). 
This vast diversity is made possible through the evolution of an elegant process of 
DNA recombination of separate multi-gene families of immature naïve B cells. This 
gradual recombination event eventually forms functional individual immunoglobulin 
genes as the B cells mature in the BM (23). An Ab is a secreted version of the 
membrane bound BCR receptor. The IgH and IgL chains that build up an Ab form a 
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complex of approximately 160 kDa. The C-terminal domain of both IgH and IgL are 
constant, and the constant IgH domain defines the isotype of the Ab, which in turn 
defines the effector function. The N-terminal domain of both chains are variable, 
consisting of 3 hypervariable regions, termed complementarity determining regions 1-3 
(CDR1-3) and 4 stable regions, termed framework regions (FR). Together these 
domains define the specificity of the Ab. The variable domain of IgH consists of three 
different fused gene segments termed: variable (V), diversity (D) and joining (J) 
segments. The variable domain of IgL consists of only V and J segments (Figure 1).  
 
Figure 1: Schematic representation of an IgG antibody. Left: An antibody is composed of two IgH 
and two IgL chains. Middle: Each Ig chain consists of one variable and one constant domain. The 
variable domain of IgL is encoded by one V- and one J segment. The variable domain of IgH is encoded 
by one V-, one J- and one D segment. Right: Each of the variable domains is composed of three 
hypervariable regions called complementarity determining regions 1-3 (CDR 1-3) and four framework 
(FR) regions. The most variable region of the antibody is CDR3, which comprises the end of the V 
segment, the whole D segment and the first part of the J segment. Illustration by Mattias Karlén. 
 
The number of gene segments in each locus for V, D and J varies between mouse 
and human and between different strains of mice though the general organization is 
homologous. The IgH chain locus of BALB/c mice consists of more than 100 
functional V segments that are grouped into several different families, 13 D segments 
and 4 J segments. These segments are followed by 8 different gene segments that can 
build up the constant region (reviewed in (24)) (Figure 2). The IgL chain can be 
constructed from two different loci, the κ- and the λ-loci that are found on different 
chromosomes. As for the IgH locus, they also contain a large number of different V- 
and D segments. These segments will combine through clone-specific recombination 
events to form a single immunoglobulin gene for the IgH chain and a single 
immunoglobulin gene for the IgL chain (reviewed in (22)). The number of different 
segments in the immunoglobulin locus and the process through which the V(D)J 
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segments recombine create an enormous variability in the Ab repertoire. As each locus 
includes two chromosomes, each B cell could in theory produce two different Abs. This 
is however avoided by a process known as allelic exclusion, which ensures that each B 
cell only produces BCRs of one specificity (25, 26). A brief account of the VDJ 
recombination process is described in Figure 2 (reviewed in (22)).  
 
 
Figure 2. Gene segment layout and VDJ rearrangement of the IgH locus in mouse. The Rag-1 and 
Rag-2 enzymes are responsible for the recombination events of the immunoglobulin gene segments and 
are almost exclusively expressed in developing lymphocytes. The Rag proteins initially target a selected 
D-J segment of the IgH chain. Upon initiation of double-stranded breaks, the DNA repair machinery of 
the cell will join D and J in a non-homologous manner, and another enzyme, TdT, will add non-germline 
nucleotides into the sequence to make it complete. As the B cell progresses into a pro-B cell, Rag will 
join a single V segment with the rearranged DJ segment in the similar way. The resulting VDJ segment of 
the pro-B cells is then connected with a gene segment for the constant domain by splicing events at the 
RNA level. The variability in the N-terminal domain of the Ab provided by the different VDJ segments is 
then further enhanced by different mechanisms of repairing non-homologously joined DNA. Illustration 
by Mattias Karlén. 
 
 
3.2 NAÏVE B CELL EVOLUTION IN THE PERIPHERY 
3.2.1 B cell homeostasis in the periphery 
Immature naïve B cells that exit the BM home to the spleen where they continue 
development into mature naïve B cells that can populate other secondary lymphoid 
organs (SLOs) such as the lymph nodes (LNs). In these organs, B cells can recognize 
and become activated by foreign Ags. The differentiation and maintenance of naïve B 
cells in the periphery are dependent on the expression of the BCR, as conditional 
deletion of the BCR on B cells was shown to induce cell death of most peripheral B cell 
compartments (27). In the spleen, immature naïve B cells arriving from BM will go 
through three developmental transitional stages termed transitional stage 1, 2 and 3 
(T1-3) (28), as they differentiate into mature naïve B cells. In the mature state the cells 
can be further subdivided into follicular B cell and marginal zone B cell (MZB) 
subsets. Variants of this model have been put forward that suggest that T2 cells can be 
present in both the periphery and the BM (29, 30). Also, follicular B cells and MZBs 
may develop directly from T2 cells with the T3 stage being a dead end pathway that 
leads to anergy (31). B cells surviving the transitional stages will develop into follicular 
B cells that can populate the spleen and the LNs or to MZBs that reside in the spleen. 
The proportion of transitional B cells that mature into follicular B cells is significantly 
  6 
greater than the proportion that mature into MZBs. The factors that regulate this fate 
decision are not known, but Ab specificity is thought to be critical as some specificities 
are prone to preferentially drive the development of one or the other population (32-
34).  
It has been suggested that only about one third of the transitional B cells that exit 
the BM survive to populate the mature B cell pools (35, 36) and the cells that persist 
have a skewed BCR repertoire (37, 38). Using the anti-hen egg lysozyme (HEL) mouse 
model in which B cells exclusively express BCRs with affinities for HEL and the HEL 
transgenic mouse in which HEL has been rendered a “neo-self-ag”, it was further 
shown that self-reactive B cells are excluded from the mature naïve B cell pool within 
the follicles of the spleen. This process correlated to the level of self ligand that was 
present as well as to the affinity of the BCR for this ligand (39). In agreement with this, 
it has also been shown that a large number of immature B cells that exit the BM show 
self reactive properties and that these reactivities are significantly reduced during 
transitional maturation in both mice and humans (20, 40). In conclusion, these data 
implies that B cells undergo a second negative selection process in the periphery that is 
dependent on the BCR specificity. Furthermore, using the same HEL transgenic mouse 
models as described above, Cyster and colleagues made the intriguing finding that in 
the absence of a diverse repertoire of non-self B cells, self-reactive B cells are not 
deleted in the periphery but instead are allowed to enter B cell follicles of the SLOs as 
mature B cells (41-43). Since self-reactive B cells were allowed to mature in the 
absence of competition with non-self B cells, the authors hypothesized that B cells in 
the periphery not only compete for survival based on self-/non-self BCR recognition, 
but also for a tropic factor. This factor was suggested to be produced by cells within the 
SLOs. There is now growing evidence suggesting that this tropic factor is B 
Lymphocyte Stimulator (BLyS).  
 
3.2.2 The role of BLyS for the survival of peripheral naïve B cells 
BLyS (also called BAFF) was discovered simultaneously by several groups while 
searching the genome for additional members of the TNF family of ligands and 
receptors (44-48). BLyS is described as a survival factor for B cells in the periphery, 
and is produced primarily by macrophages, monocytes and dendritic cells (DCs) (49). 
Though BLyS can bind two receptors, called TACI and BCMA, the most profound 
effect of BLyS on naïve B cells is seen upon signaling through the BLyS receptor 3 
(BR3) (50-52). Specifically, BLyS has been shown to have a critical role for B cell 
survival during the transitional stages (53-55) and increased levels of BLyS leads to a 
substantial increase in the population of surviving T2 cells that can enter the mature B 
cell pools (56). The importance of BLyS for the maintenance of mature naïve B cells 
has been demonstrated using two experimental approaches. First, blocking BLyS 
signaling with Abs led to a rapid depletion of naïve B cells, and second, mice deficient 
in BLyS showed significantly reduced numbers of mature naïve B cells (57, 58). 
Conversely, transgenic mice constitutively over-expressing BLyS show B cell 
hyperplasia and signs of autoimmunity (44, 59). In support of this finding, patients with 
certain autoimmune diseases have been shown to display elevated levels of systemic 
BLyS (60-62). These findings may indicate that levels of BLyS are limiting under 
physiological conditions since the number of B cells has not reached a maximum.  
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The fact that deletion of autoreactive peripheral B cells overlaps with the 
developmental point when B cells become responsive and dependent on BLyS to 
survive, suggests that BLyS could have a role in the selection of the naïve B cell 
repertoire. To further study this, Lesley and colleagues (63) and Thien and colleagues 
(40) performed the following experiments using the above mentioned HEL transgenic 
mice models: Lesely et al. could show that autoreactive B cells (anti-HEL B cells) were 
more susceptible to reduced levels of BLyS in the HEL transgenic mice than B cells of 
non-self specificities. Thien et al. showed that self-reactive anti-HEL B cells could 
indeed mature and gain access to the B cell follicles even in the presence of competing 
non-self B cells if the levels of BLyS were experimentally elevated. While these results 
support the role for BLyS in the selection of naïve B cell specificities and others have 
later shown similar results (64, 65), they were derived from experiments based on 
transgenic mice models having a restricted BCR repertoire. It will therefore be 
important to study the role of BLyS under more physiological conditions. The way 
BLyS is thought to affect and control naïve B cell survival together with BCR is not 
fully understood. One model that was suggested by Mackay and Browning (66) 
propose that self-reactive immature B cells need stronger survival signals by BLyS than 
non-self B cells due to the strong BCR signaling that is induced in these cells upon 
BCR ligation. In line with this model, crosstalk between downstream components of 
the BCR- and the BR3 signaling pathways was identified where the BCR signaling was 
proposed to provide the BR3 signaling pathway with rate-limiting substrate (67).  
Since BR3 is also expressed on germinal center (GC) B cells, BLyS may also 
have a role in the survival of GC B cells. Less is known about this, but it was shown 
that the maintenance and development of high affinity Abs were dependent on BLyS 
signaling but the initiation of GCs was not (68, 69). 
 
3.3 ORGANIZATION OF SECONDARY LYMPHOID ORGANS 
Secondary lymphoid organs, such as the spleen and LNs, serve to substantially 
increase the probability that naïve B cells and helper T cells meet their cognate Ags. 
These organs have a highly organized dynamic structure of non hematopoietic cells that 
creates a meeting point for numerous immune cells required for specific B- and T cells 
to become activated. While LNs drain the lymphatics and can sample Ags via the 
lymphatics from all over the body, the spleen filters the blood and is mainly specialized 
to provide immune activation against blood born infections (70). A sectioned spleen 
displays white circular areas scattered throughout the whole interior (Figure 3A). This 
so-called white pulp consists of lymphocytes and various innate immune cells. The 
white pulp is surrounded by a much larger area, the so-called red pulp, which consists 
of mainly recirculating erythrocytes and macrophages. The red pulp functions primarily 
to filter the blood and remove old erythrocytes as well as recycle iron (70). The white 
pulp is the site of activation for naïve lymphocytes and thus where the adaptive 
immune response is initiated. The white pulp of the spleen has a very similar structure 
and function to the structure and function of the LNs (Figure 3B). T cells form close 
conjugates with conventional DCs in the center surrounded by B cell areas referred to 
as B cell follicles. This is where the naïve follicular B cells reside. Apart from B cells, 
special resident follicular dendritic cells (FDCs) are also present here. In spleen, the 
border between the white and the red pulp is lined by the marginal zone (MZ) 
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consisting of innate like MZBs. The blood drains from the central arteriole to the 
marginal sinus, a vessel dividing the B cell follicles from the marginal zone. From here, 
the blood can continue out in the red pulp or into the white pulp via specific conduit 
networks. The LN is surrounded by the subcapsular sinus in which the afferent lymph 
drains as it enters the LN. The lymph continues through the LN either via large 
trabecular sinuses or via conduit networks to the center of the LN, the medulla, on its 
way out through the efferent lymph (Figure 3) (reviewed in (71)). 
 
 
Figure 3. General structure of secondary lymphoid organs: (A) Spleen. Left panel: The white pulp of 
the spleen is embedded within the red pulp. The T cell zone is localized in the center of the white pulp, 
surrounded by B cell follicles, the marginal sinus and the marginal zone. Blood enters the white pulp 
through the central arteriole. One way for Ags to enter the white pulp is via the conduit network. Right 
panel: Confocal microscopy image of a spleen section. Blue: anti-IgD staining indicating B cell follicles 
within the white pulp. Red: MOMA-1 staining macrophages lining the marginal sinus. Green: anti-IgM 
staining IgM+ extrafollicular foci in the red pulp and MZBs surrounding the marginal sinus. (B) Lymph 
node. Left panel: The center of the LN is referred to the medulla, with the surrounding T cell rich 
paracortex and B cell follicles and the subcapsular sinus. Lymph enters the LN via afferent lymph vessels 
and drains into the subcapsular sinus via trabecular sinuses or via the conduit network and leaves the LN 
through the medulla in the efferent lymph vessel. The high endothelial venules (HEVs) allow for entry 
and exit of lymphocytes. Right panel: Confocal microscopy image of LN. Green: anti-TCRβ indicating T 
cell rich area in the medulla and paracortex. Blue: anti-IgD indicating B cell follicles. Red: PNA binding 
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3.4 ACTIVATION OF ANTIGEN-SPECIFIC B CELL RESPONSES 
3.4.1 Presentation of antigen to naïve B cells 
In order for an Ab response to be elicited towards an invading pathogen or a 
vaccine Ag, a naïve B cell that recognizes a pathogen- or vaccine-associated Ag needs 
to internalize the Ag and present fragments of it on major histocompatibility complex 
(MHC) class II for further activation by cognate helper T cells. The way Ag reaches B 
cells remained poorly defined for many years until recent developments in high 
resolution imaging techniques helped reveal these events in greater detail. Different 
mechanisms have been described for how Ags can enter the SLOs and each depends on 
the nature of the Ag. Very small Ags (<70 kD) can reach the B cell follicles directly by 
diffusion through pores that are present in the subcapsular sinus (72) or by travelling 
via a special conduit system consisting of collagenous fibres (73). Larger Ags on the 
other hand, reach the naïve B cells of the SLOs in a cell-associated manner via the 
formation of immune complexes or complement-coated immune complexes that will be 
recognized and captured by Fc-receptors and complement receptors on specific cells. 
Examples of such cells are macrophages that are present next to the subcapsular sinuses 
that have been shown to present Ag to cognate B cells themselves, or to hand over the 
Ag directly or indirectly to FDCs that can then present the Ag to cognate B cells (74-
76). Unlike the classical DCs present in the rest of the body, the FDCs are not of 
hematopoietic origin and they are thought to lack the capacity to present peptides on 
MHC class II molecules (reviewed in (77)). Their main function is to present Ag to 
naïve and activated B cells by capturing immune complexes on Fc-receptors or 
complement receptors (71). In spleen, MZBs have been implicated in the transport of 
Ag complexes to the FDC (78). Classical re-circulating DCs expressing MHC class II 
are present in the T cell zone for activation of T cells, but can also present Ag to B cells 
that are passing on their way to the follicle. Apart from their capacity to present peptide 
on MHC class II to activate T cells, these DCs have been shown to internalize Ag via 
the FCγRIIb in the form of immune complexes in a non-degradative manner to later 
recirculate the Ag on their surface for presentation of the protein to B cells in its native 
form (79, 80). 
 
3.4.2 Fate of activated B cells 
When B cells have internalized Ag they begin to increase their expression of the 
receptors CCR7 and EBI-2, which together facilitate their movement to the B cell-T 
cell border in the SLOs where they can meet and receive help from cognate T helper 
cells (81-83). The B cells will at this point also up-regulate surface expression of MHC 
class II and increase responsiveness to CD40 signaling in order to facilitate T cell help 
(84). A cognate T helper cell that recognizes MHC class II with peptide on the naïve B 
cell via its T cell receptor (TCR) will provide further signals to the newly activated B 
cell by for example CD40L and ICOS (85). This leads to proliferation of the Ag-primed 
B cell. The proliferating B cells can after a day or two of initial proliferation at the B-T 
border take either of three pathways, by differentiating into extrafollicular PCs, early 
non-GC recirculating memory B cells or GC B cells (86-88). It is not fully understood 
which signals affect this fate decision though it has been suggested to depend in part on 
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the initial affinity of the BCR for Ag. Affinities above a certain threshold lead to the 
formation of extrafollicular PCs while lower affinity lead to the initiation of GC 
formation (89). In a recent publication it was suggested that B cells at the B-T border 
that were able to up-regulate the highest density of cognate MHC class II presenting 
peptide on their surface could compete favorably for access to T cell help and thereby 
enhance their chance to enter the GC compared to B cells that were not able to present 
as high densities of MHC class II on their surfaces (90).  
Extrafollicular responses are dependent on continuing expression of EBI2 (91) 
and mediate the production of Ag-specific Abs very quickly after an infection. They are 
therefore likely to be an important part of the immune response to invading pathogens. 
These cells are however of relatively low affinity for the Ag and will die within a few 
days without forming any type of memory against the Ag. These cells are therefore not 
a desirable immune response in a vaccine setting, which is dependent on the formation 
of memory cells.  
 
3.4.3 Follicular helper T cells 
As mentioned previously, B cell survival requires cognate T cell help. The 
specific CD4+ T cell subset that provides this help within the SLOs is termed follicular 
helper T (Tfh) cells (reviewed in (92)). Tfh cells have specific attributes that separate 
them from other CD4 expressing T cells of the immune system. The Tfh cell program 
is thought to be initiated in the naïve CD4+ helper T cells present in the T cell zone of 
the SLOs through the initial contact with conventional DCs present in these areas. The 
affinity of the TCR to the MHC class II with peptide presented by the DC is thought to 
be of importance where high affinity has been suggested to lead to the formation of Tfh 
cells (93). Tfh cell differentiation is further associated with the signaling by ICOS-L on 
DCs and ICOS on the naïve T cell. This receptor ligation leads to up-regulation of the 
transcription factor Bcl-6 that is crucial for the development of Tfh cell characteristics 
in comparison to other CD4+ helper cells expressing the transcription factor Blimp-1 
(93-96). Furthermore, Tfh cells are defined as CXCR5+ CCR7-, which is important for 
their movement from the T cell zone to the B cell follicular areas (97-99). After DC 
priming, Tfh cells are thought to receive further signals from the Ag-specific newly 
activated B cell at the B-T border to completely develop Tfh cell characteristics (92) 
and enter the GC reaction where they will continue to provide survival signals to 
activated and proliferating B cells. The cytokine that has been mainly associated with 
Tfh cell stimulation of B cells is IL21, which is a critical cytokine for optimal GC-B 
cell proliferation and the differentiation and survival of PCs in the SLOs (100-102). 
Interestingly, PCs themselves have been suggested to provide negative feedback 
regulation for the development of Tfh cells by acting as antigen presenting cells 
without providing IL-21 stimulation or up-regulation of Bcl-6 in the naïve T cell. This 
mechanism is thought to lead to the suppression of Tfh cell development when the 
appropriate level of PCs has been reached (103). The fate of Tfh cells after primary 
activation is not well understood but it was recently suggested that Tfh memory cells 
can form and that they retain the plasticity to form other T helper subset upon re-
challenge (104).  
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3.4.4 Germinal center formation and affinity maturation 
In contrast to the formation of extrafollicular short-lived B cells, the more desired 
outcome of a vaccination is the formation of GCs (Figure 4). These GCs will lead to the 
production of high affinity, isotype switched memory B cells and long-lived PC. After 
the B cells have been primed by Tfh cells at the B-T border, some are programmed to 
home back to the B cell follicle by retaining their expression of CXCR5 and down-
regulating EBI2 (91), and together with other cells form the microenvironment of a GC. 
The GC forms upon proliferation of activated B cells and is divided into two areas, the 
T cell zone proximal dark zone (DZ) with highly proliferating B cells, and the light 
zone (LZ) where Ag-dependent B cell selection takes place (105).  
 
 
Figure 4. Structure of germinal centers.  Left: Germinal centers form in the B cell follicles of SLOs 
and are divided into a dark zone and a light zone. Activated B cells proliferate within the dark zone where 
somatic hypermutation and isotype switching of the BCRs occur. The B cells are then directed into the 
light zone where the BCR affinity for the Ag is tested on Ag-presenting FDCs. B cells with high affinity 
are provided further survival signals from Tfh cells and either exit the germinal center as memory B cells 
(mB cells) or long-lived plasma cells (LLPC), or they re-enter the dark zone for further proliferation. 
Right: Confocal microscopy image of a germinal center in the inguinal LN of a mouse. Red: Anti-TCRβ 
indicating T cell rich area in the paracortex. Blue: Anti-B220 indicating B cell follicles. Green: GL7+ 
germinal center lymphocytes. Illustration by Mattias Karlén. Adapted from: McHeyzer-Williams, M et al. 
2011. Molecular programming of B cell memory. Nat Rev Immunol. 12:24-34.  
 
The GC consists of different cells that are important for its persistence. The most 
abundant cell type is the activated B cell. These B cells differ from the naïve B cells by 
their high expression of Fas and n-glycolylneuraminic acid (the ligand for the GL7 Ab 
which also binds to PNA), their loss of IgD and the fact that they are fast dividing cells 
(106-108). Compared to the naïve B cells, GC B cells have up-regulated levels of the 
transcription factor Bcl-6 (109), which among other things are important to keep the 
GC-B cell from apoptosis and from leaving the GC prematurely (110, 111). B cells 
move between the DZ and the LZ depending on their expression of CXCR4 (112). In 
contrast to what was believed previously (113), the B cells of the DZ and the LZ are 
indistinguishable in terms of size and morphology and show similar behavior in terms 
of movement within their compartments (114, 115). The LZ is where newly divided B 
cells are exposed to cognate Ag presented by the FDCs. As mentioned previously, 
FDCs are specialized in trapping immune-complexes on their surface primarily with 
complement receptors, and present Ag to B cells as they enter the LZ. In addition, they 
  12 
are also producing chemoattractants and cytokines important in the formation of GCs 
(116). The LZ also include the Tfh cells that are essential for GC affinity maturation of 
B cells and GC maintenance. Another important cell within the GC is the tingible-body 
macrophage that is responsible for clearing the apoptotic B cells from the GC (117).  
B cells proliferating in the DZ of the GC go through affinity maturation of their 
BCRs through a process known as somatic hypermutation (SHM). This process is 
dependent on the activation-induced cytidine deaminase (AID) enzyme (118). AID 
induces cytosine deamination of nucleotides within the variable regions of the 
immunoglobulin genes as the cells divide. The resulting uracil is then excised by uracil 
DNA glycosylase and the DNA is repaired by error prone DNA polymerases, which 
will introduce point mutations. These mutations hence provide B cells with non-
somatic immunoglobulin genes, which further diversify the B cell repertoire. During 
the GC reaction, the BCR also isotype-switch from IgM to IgG, IgA or IgE in an AID-
dependent process (85). At some point, the B cells will stop proliferating in the DZ and 
enter the LZ where they will test their newly formed BCR for binding to Ag presented 
on the FDCs. If the affinity for the Ag is lost, is of low affinity or have developed 
affinities for self-Ags, the B cells will apoptose (85). However, if the affinity for the Ag 
is equal or better they will acquire survival signals from Tfh cells. Low affinity for Ag 
has been shown to be enough for B cell survival in the GC but in the presence of high 
affinity B cells, B cells of lower affinity will die (119, 120), indicating that B cells may 
be able to compete for survival. It is unknown whether the Ag-dependent selection for 
survival in GCs is based on limited presence of Ag or limited presence of T cell help or 
if both mechanisms are in play (116). Surviving B cells can take either of three 
pathways, re-enter DZ for increased SHM, exit the GC as a long-lived Ab-secreting PC 
or as non-secreting memory B cell (Figure 4). 
 
3.4.5 Memory B cell responses 
Memory B cells are classically defined as affinity matured IgG+ B cells that are 
formed in the GC reaction. These cells will home to the SLOs and circulate throughout 
the organism until a secondary Ag encounter, when these memory B cells will rapidly 
differentiate into effective ASCs (121). Recently, additional subsets of memory B cells 
have been identified. These include somatic hypermutated GC-dependent and non-
mutated GC-independent IgM+ memory B cells (86, 122, 123) as well as non-mutated 
non-GC dependent IgG+ memory B cells (86). However, the specific functions of these 
cells remain enigmatic. It is also currently debated whether or not memory B cells can 
re-enter GCs upon secondary encounter of the Ag. In this regard, it has been proposed 
that only the IgM+ memory B cells can do so whereas the IgG+ memory B cells 
immediately differentiate into ASCs (72, 122). In contrast to B cell survival in the GC, 
survival of memory B cells is thought to occur independent of Ag (124).  
Long-lived PCs are generated from GCs as terminally differentiated ASCs that 
can be considered a distinct lineage of the memory B cell response. Long-lived PCs are 
thought to survive in the periphery independently of memory B cells (125) and in 
comparison to memory B cells, long-lived PCs express BCRs of higher affinity (126, 
127). Commitment to the PC compartment requires up-regulation of the transcription 
factor Blimp-1, which is referred to as the master regulator of PC differentiation. 
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Blimp-1 was shown to be expressed in a subset of GC B cells (128), indicating that the 
decision of becoming a long-lived PC probably happens within the GC. Blimp-1 
expression induces the expression of the transcription factor XBP-1, and both are 
needed for normal PC development (129). The signals that determine the fate of the 
surviving GC B cells are poorly understood but asymmetric cell division of the B cells 
could be involved (130). Furthermore, despite being well appreciated that the GCs are 
necessary for the development of long-lived PCs, it was recently shown conversely that 
long-lived PCs could arise outside of GCs (131). This finding indicates we may not 
fully understand the factors important for the formation of long-lived PCs.  
The majority of long-lived PCs home to the BM where they may survive for the 
lifetime of an individual thanks to specific survival niches of stromal cells, which 
provide an optimal cytokine milieu for these cells. Important retention and survival 
signals expressed by the stromal cells include the secretion of IL-6, expression of the 
adhesion molecule VCAM1, and the expression of BLyS (132).  
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4 VACCINES 
4.1 INTRODUCTION TO VACCINES 
As far back as 400 B.C. the observation was made that individuals who recovered 
from a specific disease rarely got the same disease again. We now know this is the 
hallmark of vertebrate immune systems. The cells that make up our immune system 
have two main functions: firstly, they recognize harmful pathogens as non-self and 
clear them, and secondly, they develop memory for that specific pathogen to prevent 
disease following secondary exposure. This system can be exploited to develop 
vaccines with the goal to attain memory for specific pathogens without causing 
perturbations associated with natural infection. In general for acute pathogens the more 
a vaccine mimics normal infection the more efficient it is. When it comes to vaccines 
against chronic pathogens however, the vaccine may need to be constructed in such a 
way that it elicits a more potent immune response than that elicited during natural 
infection. 
 
4.1.1 History of vaccination 
Towards the end of the 18th century British physician Edward Jenner (1749-1823) 
documented experiments testing vaccination, which eventually resulted in the potent 
smallpox vaccine and eradication of smallpox. At this time, smallpox was a common 
disease with a mortality rate of about 30% (133). Jenner made the observation that 
milkmaids, who often became infected with a related cowpox virus only showed mild 
signs of infection by cowpox, and rarely became subsequently infected by smallpox-
causing variola virus. Jenner hypothesized that the milder cow version of the pathogen 
could help protect humans against the more aggressive smallpox. He thus performed 
experiments in which he inoculated individuals with lesions from cowpox infections. 
He then challenged these individuals with lesions from variola virus-infected 
individuals and confirmed his theories about immunity. Remarkably, this was all done 
at a time when people were ignorant about infectious agents and viruses and bacteria 
had not yet been discovered as the etiological agent of infectious diseases. The next 
important milestone in the history of vaccination was marked by the discovery by Louis 
Pasteur (1822-1895) that attenuated pathogens could be used for vaccination.  
 
4.1.2 Live attenuated and inactivated vaccines 
Live attenuated vaccines remain in use today to protect against certain pathogens. 
These vaccines are potent since they moderately replicate and thus provide the immune 
system with innate stimuli that increase the potency of the adaptive responses (134). All 
ways by which this occurs are still not entirely understood. Historically, live attenuated 
vaccines were prepared on the principle of Jenner’s smallpox vaccine, using a related 
virus, adopted to infect other species than humans. Guided by the experiments of 
Pasteur, pathogens were later attenuated by physical means. For example, the rabies 
vaccine was developed by drying the rabies virus. More modern ways of attenuating 
pathogens are to grow them in vitro in eggs or in cell culture or by growing the 
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pathogen at low temperature. These treatments weaken pathogens sufficiently to reduce 
pathogenesis in humans. The very efficient mumps, measles and rubella (MMR), 
yellow fever, varicella, oral influenza and oral polio vaccines are all examples of 
vaccines that have been produced using these methods (135). However, because 
attenuated vaccines have the risk of reverting back to their infectious form in humans, 
modern vaccines are often based on individual Ags cloned and expressed by molecular 
DNA technology as recombinant proteins or virus-like particles (VLPs), or as 
recombinant viruses where the Ag is inserted into a heterologous vector based on a 
non-pathogenic virus (135). Many of these vaccines are however still only 
experimental and not yet approved for human use, with the exception of the VLP-based 
vaccines against hepatitis B virus and human papilloma virus that are already in use. 
Inactivated vaccines are, as the name implies, vaccines in which pathogens have 
been inactivated by different means to render them non-infectious. These vaccines 
include intact protein Ags for the immune system to recognize but their genomes are 
unable to replicate. Inactivated vaccines are commonly prepared via chemical treatment 
with for example formaldehyde or by irradiating the pathogen with UV light. Examples 
of inactivated vaccines that are used today are vaccines against tick-borne encephalitis 
and polio, as well as the annual influenza in which the inactivated virus is partially 
purified to contain Ags of interest.  
For vaccines to mount a potent adaptive immune response, activation of the 
innate immune system is also critical. Innate immune cells can become activated 
through various specific pathogen recognition receptors via components that are 
produced during replication of pathogens. Examples of such components are bacterial 
and viral DNA and RNA and pathogen associated lipids and sugars. Hence, due to the 
lack of replication of inactivated vaccines, they will not be as potent as attenuated 
vaccines and therefore require the addition of an adjuvant. Many adjuvants activate 
innate immune cells specifically by targeting pathogen recognition receptors, but others 
have other or unknown mechanisms of action (136-138).  
 
4.1.3 Vaccines based on recombinant proteins 
With modern recombinant DNA technology it is possible to create vaccines 
based on the Ag that is the main Ab target of the pathogen (subunit vaccines). These 
vaccines can be formulated with appropriate adjuvants for more effective and more 
specific Ab elicitation. The purified proteins may be further modified to meet specific 
needs of a vaccine. For example, the vaccine against pertussis caused by the bacteria 
Bordetella pertussis, is based on the toxin produced by the bacteria. In this case, the 
toxin has been rendered non-toxic without affecting the structure of antigenic 
determinants required to elicit neutralizing Abs (139). Additional examples of subunit 
vaccines include the annual influenza vaccine and the modern rabies vaccine (140). 
Here, virus particles grown in vitro are inactivated, and then fractionated by detergents 
to only include the parts of the pathogen that are needed for the induction of 
neutralizing Abs, so-called split detergent vaccines. Even more sophisticated methods 
were used to develop the hepatitis B vaccine. In this case, the main component of the 
vaccine, the virus envelope protein HBsAg, was produced in vitro in large quantities at 
low cost. Previously, the only source of HBsAg was limited to the plasma of infected 
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people since hepatitis B virus can only infect and replicate in humans (141). Another 
example of a protein subunit vaccine is the recently developed vaccine against the 
human papilloma virus. Here, the target surface protein, L1, is produced in vitro to 
form VLPs by spontaneous self-assembly (135). It is thought that proteins presented in 
this form become more immunogenic than proteins that are delivered in solution (142). 
Some target Ags, such as the polysaccharides of certain bacterial pathogens, do 
normally not induce T-cell dependent responses and hence no memory response can be 
formed to these immunogens. To develop a vaccine based on these Ags, the 
polysaccharides were conjugated to proteins that included T-helper epitopes, to allow 
the formation of memory responses. Examples of conjugate vaccines include those 
against H. influenzae, Neisseria meningitidis and Streptococcus pneumoniae (141). 
Recombinant proteins can also be used as tools to investigate basic principles of 
vaccine-induced B cell responses to address fundamental questions in immunology, as 
demonstrated in this thesis. 
 
4.2 THE ROLE OF B CELLS IN VACCINE INDUCED RESPONSES 
Elicitation of Abs is the correlate of protection for most existing vaccines used 
today. The magnitude as well as the quality of the Ab response is critical for vaccine 
efficacy. It has been shown that passive immunization with pathogen-specific Abs can 
protect from infection of specific pathogens. Vaccines that allow in vivo expression of 
Ags such as DNA vaccines, recombinant viral vector-based vaccines and live 
attenuated vaccines also elicit CD8+ T cell responses that may contribute to their 
efficacy, but the role of cellular responses in vaccine-mediated protection is less well 
defined (1). As discussed earlier, long-lived PCs in the BM are the source of serological 
Ab response that may last the life of an individual (132). For example, the half-life of 
the serum Ab responses to the live attenuated measles vaccine has been estimated to 
3014 years, 542 years to mumps and 114 years to rubella. For protein subunit vaccines 
against tetanus and diphtheria the half-lives of the specific Abs were shorter and 
estimated to be 11 and 19 years, respectively (143). The long-lived PCs are responsible 
for the first line of defense against pathogen re-exposure and an important part of the 
immunological B cell memory. Many models have been put forward to explain the 
long-lived serological memory response, including memory B cell-dependent models, 
where it is proposed that the memory B cell pool continuously re-populates the PC pool 
through activation from persisting Ag in the form of immune complexes or as a result 
of polyclonal stimuli via toll-like receptors. In the last years however, an expanding 
body of data support the conclusion that memory B cells and long-lived PCs are two 
independent B cell populations and that long-lived PC survival, as mentioned earlier, 
depends on special niches in the BM where the long-lived PCs can become long-lived 
due to the specific cytokine milieu in the BM (125). In order to elicit as long lasting PC 
responses by subunit vaccines as with attenuated vaccines, it will be important to study 
attenuated vaccines or live pathogens in general, to identify the types of innate immune 
signaling these vaccines initiate at early time points of immune activation. This kind of 
information can give us important leads on how to formulate adjuvants and 
immunization regimens to generate more long-lasting B cell responses.  
In contrast to long-lived PCs, memory B cells are non-Ab producing B cells that 
can rapidly proliferate into Ab-producing PCs upon secondary encounter of the Ag 
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such as a booster vaccination or an infection. This recall response will be much faster 
and much more potent than the initial primary response that the memory B cells 
originally derived from (144, 145). Both types of B cells are critical in the development 
of vaccines.  
 
4.3 VACCINES AGAINST VARIABLE PATHOGENS 
Most vaccines that are used today have been developed by empirical methods 
based on similar principles as used during the 19th century. This includes the isolation, 
inactivation or attenuation and injection of the specific pathogen. These vaccines offer 
protection against pathogens that are genetically stable or against pathogens that only 
vary from one year to another, like the yearly influenza viruses, but that means a new 
vaccine has to be generated every year. These vaccines are also efficient against 
pathogens that are present in a limited number of serotypes making it possible to 
develop a vaccine that includes Ags from all variants (Figure 5). What is also common 
to most pathogens for which there are vaccines today is that they cause a primary 
infection that humans, or at least a large percentage of the human population, are able 
to clear without having a pre-existing immunity. It is therefore possible to study the 
specific mechanisms the body uses for protection, referred to as the correlate of 
protection and to design vaccine candidates that induce similar immune parameters. 
The most common correlate of protection for the successful vaccines in use today is the 
induction of Abs directed against surface structures of the pathogen. 
 
Figure 5. Implications of antigen variability on vaccine development. Most licensed vaccines are 
towards pathogens with little or no variability in their antigens. The vaccines against Pneumococcus 
(Streptococcus pneumoniae) and Meningococcus (Neisseria miningitidis) are multivalent vaccines that 
include immunogens from up to 14 serotypes. For influenza, for which the circulating strains vary every 
year, an annual vaccine has to be prepared. The correlate of protection for vaccines against all listed 
pathogens/diseases is elicitation of antibodies. For variable pathogens such as HIV-1 and HCV there are 
no vaccines available.  
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5 VACCINE INDUCED B CELL RESPONSES TO HIV-1 
ENV 
5.1 INTRODUCTION TO HIV-1 
5.1.1 Classification and genetic variability 
Upon the initial isolation of HIV-1 from human LNs, the virus was found to 
express reverse transcriptase and have similar shape and size as other retroviruses and 
was therefore identified as a member of the Retroviridae family. The cloning and 
analysis of the viral genome further classified the virus in the genus of lentiviruses. As 
with other lentiviruses, HIV-1 causes slow disease progression and its primary cell 
targets are lymphocytes and macrophages of hematopoietic origin. When phylogenetic 
analyses of HIV-1 viruses from different parts of the world were performed, it became 
clear that this was an extremely genetically variable virus. Most of the variation can be 
attributed to the surface Env protein. HIV-1 isolates are divided into three main groups: 
M (main), O (outlier) and N (non-M, non-O). The M group is further divided into the 
following subgroups referred to as clades: A, B, C, D, E, F, G, H, J and K, as well as 15 
recombinant forms (CRF). The amino acid sequence between clades differs by 
approximately 30% and within one clade the difference can be up to 20% (146). Soon 
after the isolation of HIV-1, several distinct lentiviruses infecting primates were 
discovered. They were named simian immunodeficiency virus (SIV), but in contrast to 
HIV-1 they show asymptomatic infections in their hosts. It is now well established that 
HIV-1 and HIV-2, a less pathogenic variant of HIV-1 (147), originate from at least two 
different strains of SIV (148), and are thought to have been transmitted from primates 
to human some time near the early years of the 20th century (149).   
 
5.1.2 Therapy and the need for a vaccine 
 Today in the world, there are over 34 million people infected with HIV-1 and 
every year an estimate of 1.8 million people die of AIDS (numbers retrieved from the 
United Nations program on HIV/AIDS, UNAIDS, www.unaids.org). The development 
of anti-retrovirals for slowing the onset of AIDS increased during the 90s, and today, 
many HIV-1 infected people can live their whole life without developing AIDS. These 
drugs are targeting several steps of the viral life cycle and can keep the viral replication 
to a minimum. However, this medical treatment is primarily available for HIV-1 
infected individuals in the western world. To reduce the rate of HIV-1 transmission 
globally, a preventative vaccine is of outmost importance. Most current HIV-1 vaccine 
research focuses on the use of vectors and/or DNA plasmids aimed at eliciting an 
effective T cell response or subunit protein-based vaccines aimed at eliciting protective 




  19 
5.1.3 The Envelope glycoproteins 
Since Env is the only viral protein present on the surface of HIV-1 it is a central 
target for a prophylactic Ab-based vaccine. The functional Env glycoprotein is a 
transmembrane-spanning trimer whose main function is to bind the primary host cell 
receptor, CD4, and the co-receptor, CCR5 or CXCR4 to mediate viral entry (Figure 6). 
The Env trimer complex is formed by three heterodimers associated through non-
covalent binding. Each heterodimer is initially produced as a single protein, gp160, 
which is then cleaved in the Golgi apparatus of the infected cell into an external 
glycoprotein, gp120, and a transmembrane glycoprotein, gp41. Together the trimeric 
heterodimers form the Env glycoprotein complex (reviewed in (150)). The complete 
structure of Env in its un-liganded form has so far not been solved, but truncated 
versions of monomeric gp120 in complex with soluble CD4 and/or specific Abs were 
crystallized and the structures solved (151-157). In addition, low resolution structures 
of the un-liganded and liganded forms of Env were determined using cryo-electron 
tomography (158). This information has provided important insights into the Env 
trimer assembly in the context of the virus. Also, using the same technique, it was 
shown that the HIV-1 virus has surprisingly few spike proteins present on its surface 
compared to other viruses, an estimated 14±7 functional spikes in addition to numerous 
non-functional spikes (159-161), which may affect the capacity of Abs to bind to the 
virus with high affinity (162).Very recently the structure of the un-liganded form of 
trimeric Env was resolved using single particle cryo-electron tomography at a much 
higher resolution than presented before (Keystone meeting on HIV Vaccines 2012: 
Joseph G. Sodroski. Abstract: #2).  
 
 
                              
 
Figure 6. Primary and secondary receptors for Env. Env is present on the surface of the virus 
membrane as a trimer consisting of three heterodimers. The gp41 domain of each heterodimer includes 
the transmembrane region and the gp120 domain includes the receptor binding sites. Upon binding of 
Env to its primary receptor CD4, a conformational change in gp120 forms the binding site of the 
secondary receptors, CCR5 or CXCR4. Binding to the secondary receptor (usually referred to as the co-
receptors) allows the virus to enter target cells by fusion of the viral and cellular membranes.  
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5.2 TYPES OF ANTIBODIES ELICITED DURING CHRONIC HIV-1 
INFECTION 
Many types of Env-specific Abs with different characteristics are elicited in 
naturally HIV-1 infected individuals. The different Ab characteristics and the 
implication they have on the development of Env-based immunogens are listed below.  
 
5.2.1 Strain specific antibodies 
HIV-1 infection elicits Abs predominately directed against the highly 
immunogenic variable regions of Env (163). Since these regions tolerate an extreme 
degree of variability, escape mutants are readily selected to evade Ab recognition, 
resulting in circulating Abs that are not able to neutralize the most recently produced 
autologous viruses, but only those that were present at earlier time-points (164-167). 
Abs that target variable regions are usually referred to as strain-specific as they can 
neutralize the homologous virus (that they were elicited against), but not heterologous 
viruses. The extreme diversity of HIV-1 precludes the development of a “cocktail 
vaccine” containing different Env immunogens. Rather, it is generally appreciated that 
conserved determinants of HIV-1 need to be targeted, making this a particularly 
difficult vaccine target. 
 
5.2.2 Non-neutralizing antibodies 
A large fraction of the Ab response elicited during infection is also directed 
against conserved determinants of Env. However, in the majority of cases the Abs 
recognize conserved regions that are not exposed on the functional Env trimer present 
on the infectious particle. During an infection, it has been shown that soluble gp120 is 
readily shed from both virions and from infected cells, leaving so called “stumps” of 
non-functional gp41 (160, 161). Since the trimerization domain of the Env protein is 
located in gp41, shed gp120 dissociates into monomers resulting in the exposure of 
epitopes that are not visible on the functional spike, such as the N- and C-termini of 
gp120. Abs against these regions are therefore non-neutralizing. Shed gp120 may be 
considered to act as a decoy Ag diverting the immune response from more relevant 
targets on the functional Env trimer. Similar Abs may be generated in response to Env 
vaccination unless efforts are made to produce soluble Env trimers that are stabilized in 
a trimeric form (reviewed in (168)). 
 
5.2.3 Broadly neutralizing antibodies 
For different HIV-1 strains to infect cells with similar tropism, parts of the 
functional Env protein have to be kept conserved. Hypothetically, if an Ab can target 
such a site, it should be able to neutralize most strains of HIV-1. One of the most 
important conserved sites on gp120 is the CD4 receptor-binding site (CD4bs). Hence, 
this is a desired target for many vaccine regimens. However, most highly conserved 
determinants of the functional Env protein are efficiently shielded by N-linked glycans 
or by structural constraints that have evolved as a result of extensive immune pressure 
during viral evolution in multiple hosts over many years. These regions therefore tend 
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to be less immunogenic than the highly exposed variable regions. Interestingly, 
approximately 10% of infected individuals do eventually develop Abs that are specific 
for conserved and exposed regions of the functional Env trimer. These Abs neutralize a 
broad spectrum of primary HIV-1 viruses in standardized HIV-1 neutralization assays 
in vitro and are therefore referred to as broadly neutralizing antibodies (bNAbs). There 
is little evidence that these Abs are beneficial for the individual who develops them, 
probably due to the vast amounts of viral variants already seeded during chronic 
infection including potential escape mutants. However, in the context of a prophylactic 
vaccine setting, bNAbs may effectively block the infection, or if sterile protection is not 
achieved, blunt the acute viremia. The latter would most likely result in a lower viral set- 
point and a reduction in the number of viral transmission events to new individuals, 
which are also highly attractive goals for a prophylactic vaccine. Several bNAbs have 
been assessed in passive immunization studies, where they were shown to protect 
against challenge with chimeric SHIV viruses (2-4, 6, 7, 169-171). Another proof-of-
concept for a protective role of bNAbs in HIV infection was shown using adeno-
associated virus vectors for gene transfer of Ab-like molecules based on bNAbs against 
SIV into rhesus macaque monkeys. Vaccinated rhesus macaques monkeys showed 
stable production of the Ab-like molecules into the serum, and upon challenge with 
SIV a significant number of monkeys were protected against infection (172). 
Furthermore, using the same specialized adeno-associated virus vectors in humanized 
mice to provide a stable source of a full-length bNAb it was shown that the mice could 
be protected from subsequent HIV-1 infection (173). It is thus believed that bNAbs 
have the opportunity to neutralize virus during the short timeframe between the 
transmission event until the first latent reservoirs of the virus have been established. 
Together, these reports point to the relevance of Abs in the protection of HIV-1 and 
stimulates hope for the development of an Ab-based vaccine which, perhaps in 
combination with a T cell based vaccine, could lead to an effective prophylactic 
vaccine against HIV-1. 
 
5.3 DESIGN OF IMMUNOGENS 
5.3.1 Full length soluble Env constructs 
The first generation of Env-based subunit immunogens were generated from full 
length Env generated from T cell line-adapted clade B, MN and IIIB HIV-1 strains 
(174-177). When tested for safety in phase I clinical trials they were shown to be safe 
and elicit high levels of Env-binding Abs. When these Abs were tested for 
neutralization activity in vitro however, they were shown to only neutralize the 
homologous MN virus. Only very little to no neutralization was found against primary 
patient isolates. Ags used in the first phase III preclinical trials to test a HIV-1 vaccine 
were based on gp120 monomers. The results from these trials showed that the vaccine 
neither protected against infection nor delayed disease progression in infected 
individuals (178, 179). To better mimic Env proteins as they are presented on infectious 
virus particles, the next generation of Env immunogens was generated as stable soluble 
gp140 trimers containing both the gp120 moiety and the ectodomain of gp41 with a 
heterologous trimerization domain. To limit gp120 dissociation, the natural cleavage 
site between gp41 and gp120 was mutated (180, 181) (Figure 7). Other trimers were 
  22 
constructed where the cleavage was left intact and the trimers were instead stabilized 
by the introduction of artificial disulfide bonds between gp41 and gp120 (182, 183). A 
consistent improvement in the ability to elicit neutralizing Abs has been observed for 





Figure 7. Model of recombinant soluble trimeric Env (gp140-F). Soluble mimetics of Env were 
constructed by deletion of the transmembrane region of gp41. To keep the protein soluble as an intact 
trimer, a heterologous trimerization domain (F) was inserted in the C-terminus of the sequence. To 
further stabilize the trimer, the cleavage site normally present between gp120 and gp41 was eliminated. 
In order to make biotinylated versions of this protein, a specific biotinylation sequence (Avitag) was 
inserted following the His tag (H). This allows for specific biotinylation only at the distal part of the 
protein. The different domains, gp41, gp120, Variable region 1 and 2 (V12) and 3 (V3) are depicted in 
the model.   
 
5.3.2 Epitope scaffolds 
As discussed earlier, while bNAbs are elicited in a subset of naturally HIV-1 
infected individuals, they have so far not been induced by vaccination. A novel 
approach of immunogen design is to construct scaffold immunogens. Scaffold proteins 
are non-HIV proteins selected using computational methods for their ability to present a 
heterologous epitope of interest in its native three-dimensional conformation 
(http://www.rosettadesigngroup.com/index.php) (187). The rationale behind using 
scaffolds as immunogens is to enhance the immunogenicity of poorly immunogenic 
epitopes by stably exposing them in a more favorable way to facilitate immune 
recognition. Scaffold immunogens have been engineered to present linear gp41 bNAb 
epitopes referred to as the membrane proximal external region (MPER) epitopes, as 
well as a discontinuous CD4bs epitope (188, 189). The method for constructing a 
scaffold protein for a specific epitope begins with searching the Protein Data Bank to 
find known protein with an exposed three-dimensional structure resembling the epitope 
of interest. Selected proteins are then used for transplantation of the epitope of interest, 
or more specifically the identified homologous epitope on the selected protein is 
modified to resemble the epitope of interest even further. Next, additional mutations 
within the selected protein are inserted to keep the scaffold stable. The resulting 
scaffold immunogens are then characterized for binding to bNAbs specific for the 
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epitope of interest (190). So far, some scaffold immunogens have been shown to be 
capable of re-eliciting Abs with structural specificities similar to the original Abs (189, 
190), but Abs capable of neutralizing HIV-1 have not been induced. This approach is 
under active investigation to develop novel generations of more sophisticated scaffold 
proteins. 
 
5.4 ISOLATION OF BROADLY NEUTRALIZING ANTIBODIES AGAINST 
ENV FROM HIV-1 INFECTED INDIVIDUALS 
To identify new bNAb epitopes and to understand more about known bNAb 
epitopes on Env, efforts are underway to isolate bNAbs from infected individuals that 
display broad serum neutralization activity. Until recently, only four Env-specific Abs 
(b12, 2F5, 2G12 and 4E10) that conferred broad neutralization in a standardized HIV-1 
neutralization assay (191) were known (192-196). However, several additional broadly 
neutralizing monoclonal antibodies (MAbs) have been isolated recently using single 
cell sorting of memory B cells, or similar methods, from HIV-1 infected individuals 
whose serum displayed broad neutralization (197, 198). The detailed characterization of 
the precise epitopes of these MAbs on Env has provided valuable information. These 
analyses include Abs such as b12, VRC01 and NIH45-65 targeting the discontinuous 
CD4bs (156, 199, 200), 2F5 and 4E10 targeting a linear epitope within MPER (201, 
202) and 2G12, which targets the glycans on the gp120 outer domain, which are 
thought to have a slightly different composition compared to those present on 
endogenous glycoproteins (195, 203). Furthermore, PG9 and PG16 are two clonally 
related Abs that target a glycan-sensitive epitope at the base of the V2 and V3 domains 
that is preferentially recognized on the trimeric form of Env (197, 204). To understand 
the genetic properties of some of these Abs, the germline V(D)J immunoglobulin genes 
have been determined (200, 205). Interestingly, these analyses showed that many 
bNAbs that target the Env CD4bs use a specific IgH V gene, namely the IgHV1-2. 
Whether this is a pre-requisite for the development of bNAbs targeting the CD4bs is 
not known. An improved understanding of how bNAbs arise during natural infection 
may help guide the development of more efficient Env-based vaccine approaches.  
 
5.5 EVASION STRATEGIES OF ENV AND ITS IMPLICATION FOR 
VACCINE DESIGN 
HIV-1 has evolved several strategies to evade the elicitation of bNAbs. One such 
strategy is the high number of glycosylation sites present on Env. The gp120 monomer 
has approximately 20-25 sites for N-linked glycosylation (depending on strain) 
including both high-mannose and complex type carbohydrates. Together these sugar 
residues add up to as much as 50 % of the total mass of gp120 (206). Since these 
glycans are host-derived, they provide an effective shield that protects gp120 from Ab 
recognition (164, 207, 208). Another strategy the virus has evolved to evade immune 
recognition is the high genetic variability in exposed Env domains. The amino acid 
sequence of Env consists of five hypervariable domains (V1-V5) that are separated by 
more conserved regions. The variability arises during viral replication due to the error-
prone reverse transcriptase and to evolutionary pressure from elicited Abs (165).  
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Another hypothesis to explain the difficulties in re-eliciting broadly neutralizing 
Abs to Env by vaccination is the lack of cognate specificities in the pool of naïve B 
cells. It is possible that Env has rendered its conserved epitopes to resemble epitopes 
that are selected against in the naïve B cell pool, due to for example recognition of self 
Ags (209, 210). In other words, it is possible that HIV-1 exploits mimicry of self-
epitopes in order to evade the immune response. There are several scientific evidences 
that argue in favor of this hypothesis. First, although still a matter of debate (211), it has 
been proposed that some of the isolated bNAbs as well as the total Env-binding Abs of 
HIV-1 infected individuals have self-reactive properties in ELISA measurements (209, 
212-217). Second, it is well established that many of the characterized bNAbs against 
HIV-1 have long CDR3 loops (199), which is a common characteristics of Abs with 
polyreactive properties (20, 218, 219). Third, when some bNAbs were experimentally 
mutated back to their germline parental sequence, they were shown to completely loose 
affinity for the Env protein, suggesting that some other Ag provided the initial 
activating signal for these B cells and that B cells recognizing the conserved sites of 
Env are not present in the naïve B cell repertoire (200, 220).  
Due to the various evasion strategies mentioned, extensive efforts have been 
made to develop improved Env immunogens. Examples of such immunogen design 
includes various deglycosylation strategies (221, 222), deletion of variable regions 
(223, 224) hyperglycosylation of variable domains (225) and the stabilization of Env 
proteins in its CD4 bound site (226, 227).  
 
  25 
6 RESULTS AND DISCUSSION 
Even though soluble trimeric Env proteins are superior immunogens as compared 
to soluble monomeric Env proteins they are still not successful in eliciting bNAbs (184, 
185). In paper I, we sought to investigate the limitations of the YU2-based, soluble 
Env trimers (Figure 7) to guide future improvements of this and other immunogens. An 
initial goal was to increase the resolution of our read-outs and we therefore developed a 
differential Env-specific B cell ELISpot assay that allows the detection and 
enumeration of B cells recognizing distinct sub-regions of Env. This assay provides an 
important complement to the serological assays that are commonly used to detect Env-
specific Ab responses in vaccinated subjects today.  
In brief, B cell ELISpot assays are used to enumerate Ag-specific ASCs ex vivo 
(Figure 8A). In conventional B cell ELISpot assays, 96-well plates with specifically 
engineered membranes that allow high binding capacity of Ag are coated with the Ag 
of interest. Single cell suspensions from selected organs (spleen, BM, LN or blood) are 
then added. During over night incubation, ASCs specific for the coated Ag will bind to 
the bottom of the well. Subsequently, all cells and non-specific Abs are washed away 
and a biotin-conjugated secondary Ab specific for the Ab species is added. The assay is 
developed by the addition of enzyme-linked streptavidin and the corresponding 
substrate. Each spot visualized in the wells is a footprint of a single Ag-specific ASC.  
The number of Ag-specific B cells may be compared to the total number of IgG-





Figure 8. The principles of the B cell ELISpot assay. (A) Conventional Ag-specific B cell ELISpot 
assay. The Ag of interest is coated on the bottom of the well. Cells are added in single cell suspensions 
and Abs from Ag-specific B cells will bind to the Ag coated wells. Cells and non-specific Abs are 
washed away and the assay is developed by the addition of a biotinylated secondary Ab, streptavidin 
conjugated enzyme and substrate. (B) Optimized Ag-specific B cell ELISpot assay. In comparison to the 
conventional Ag-specific ELISpot, here, wells are coated with an unconjugated anti-mouse (for detection 
of Ag-specific murine B cells) IgG. All IgG Abs produced from the cells are therefore captured but only 
the Ag-specific Abs are visualized using a biotinylated Ag as a probe. (C) Total IgG assay. Wells are 
coated with anti-mouse IgG. All IgG Abs produced from the cells are captured and are detected using a 
secondary biotinylated anti-mouse IgG Ab. Lower panels show images of wells from respective ELISpot 
assay using Env as the Ag with cell suspensions from Env- and control (β−gal) immunized animals. Each 
spot represents the footprint of one single antibody-secreting B cell. 
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When we used the conventional ELISpot assay to detect Env-specific ASC 
responses, we observed large and quite undefined spots as well as relatively high 
background staining (Figure 8A) making the results difficult to analyze. Increasing the 
concentration of coating Ag had little or no effect on the quality of the spots. Therefore, 
to optimize the assay we coated the membranes with anti-mouse IgG Abs to first 
capture all IgG produced from ASCs in the suspension. Biotinylated Env was then 
added to visualize the Env-specific spots. Instead of chemical biotinylation, where 
added biotins could possibly shield important structures of the Ag, we constructed Env 
probes expressing a sequence for enzymatic biotinylation (avitag) at the C-terminus of 
the protein, resulting in biotinylation only at distal parts of the protein (Figure 7). With 
this improved assay format we detected well-defined Env-specific spots with very 
limited background staining (Figure 8B). This assay was further shown to be more 
sensitive than the conventional assay since we detected up to three-fold more Env-
specific ASCs. Another advantage was that we could titrate down the concentration of 
the Env probe used for detection approximately ten-fold without decreasing the signal 
strength. Furthermore, we used an Env-specific hybridoma cell line to show that the 
sensitivity of the optimized assay was similar for Env and total IgG (Figure 9). 
Together, these experiments demonstrate that the optimized ELISpot assay is highly 
specific and more sensitive as compared to the conventional method. The optimized B 
cell ELISpot assay has now been used successfully to detect ASCs specific also for 
other Ags such as IFNγ, IL2 and IgE (228) and for B cell studies in other species such 
as rhesus macaques (186, 229). 
Env is a complex protein displaying distinct structural domains with different 
antigenic properties. We therefore reasoned that it should be possible to enumerate B 
cells recognizing different sub-specificities of Env at the cellular level. This 
information may provide insights into how B cells recognize large protein Ags. 
Mapping studies to reveal Env sub-specificities contained within the polyclonal 
response were previously performed on sera using linear Env-derived peptides, 
chimeric HIV viruses and mutated Env proteins as competitive ligands in binding or 
neutralization assays (230-233). With a more sensitive B cell ELISpot assay in hand, 
we speculated that it would be possible to include additional probes such as Env 
proteins harbouring deletions of specific regions. We anticipated that by comparing the 
difference between the number of spots detected using different probes we could 
enumerate B cells that are specific for certain sub-regions of Env by subtractive 
analysis (we term this a differential ELISpot). We therefore generated a set of variant 
Env probes to be used in parallel with the trimeric gp140-F probe. The additional 
probes included: gp120-F (trimeric Env lacking the gp41 domain), gp120-F-ΔV1/2 
(trimeric Env lacking the gp41 domain and the variable domains 1 and 2), gp120-F-
ΔV3 (trimeric Env lacking the gp41 domain and the variable domain 3), gp120-F-
ΔV1/2/3 (trimeric Env lacking the gp41 domain and the variable domains 1,2 and 3) 
and monomeric gp120 protein (Figure 9A). These probes would together allow us to 
determine the number of B cells that recognize the gp41 region, the variable regions 1, 
2 and 3, the core (defined as non gp41, non V1/2 and V3 specific Abs), and gp120 
trimer-specific Abs. Successful deletion of the various regions was assessed by binding 
the probes to a panel of domain-specific mAbs. Further characterization of the probes 
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was performed using the ELISpot for detection of Env-specific hybridoma cells with 
known specificities for different regions of Env (Figure 9B).  
 
 
Figure 9. Differential Env-specific B cell ELISpot. (A) To enumerate B cells with specific sub-
specificities of Env we constructed a panel of Env-proteins to be used for probing. Each construct lacks 
one or more sub-domains. Apart from the full-length Env (trimeric gp140) used for immunization we also 
constructed gp120-F (trimeric Env lacking gp41), gp120-F-ΔV1/2 (trimeric Env lacking the gp41 domain 
and the variable domains 1 and 2), gp120-F-ΔV3 (trimeric Env lacking the gp41 domain and the variable 
domain 3), gp120-F-ΔV1/2/3 (trimeric Env lacking the gp41 domain and the variable domains 1, 2 and 3) 
and monomeric gp120 protein. (B) The different probes were characterized in the ELISpot using two 
mouse hybridoma cell lines. 5D4-F7 secreting Abs specific against V2, and 2B5-H8 secreting Abs 
specific for V3. As expected, we saw no spots in the 5D4-F7 wells probed with proteins lacking V2 and 
no spots in the 2B5-H8 wells probed with proteins lacking V3. 
 
There are a number of questions to address using the differential B cell ELISpot 
approach. We were first interested in enumerating the total Env-specific ASCs and 
characterizing the sub-specificities of Env-elicited ASCs in mice after two or three 
immunizations with soluble Env trimers. In this regard, we analyzed responses directly 
on unstimulated splenocytes harvested three days after boosting. We anticipated that 
the response detected at this time point would consist mainly of short-lived PCs that 
differentiate from Env-specific memory B cells upon Ag re-exposure in vivo. However, 
the assay may also detect non-GC derived, short-lived, low affinity ASCs elicited after 
each immunization.  
 We observed a clear difference in sub-specificities of the ASCs at different time-
points. After two immunizations, the Env-specific response was dominated by gp41-
specific B cells while after three immunizations, the response was primarily directed 
against the variable regions of Env, in particular the V3-specific region, with almost 
undetectable levels of gp41-specific ASCs. When we analyzed the Env-specific B cell 
responses in spleen at 21 days after two immunizations we could start to detect 
variable-region specific B cells. This finding indicated that these B cells develop with a 
third immunization as well as simply over time. This pattern of response to some extent 
resembles the response elicited after acute HIV-1 infection (234, 235). While further 
studies are required to understand the kinetics of the response observed for the distinct 
epitope regions of Env, it is possible that our results reflect differences in precursor 
frequencies of naïve B cells recognizing the different sub-specificities of Env, or that 
they arise from different types of naïve B cells. For example it is possible that the initial 
response to gp41 comes from naïve B cells with different characteristics such as MZBs 
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rather than the classical follicular B cells. Alternatively, gp41 and V3-specific B cells 
may induce different compositions of memory B cells that could lead to the differences 
in the recall response observed in our studies.   
The results in paper I demonstrated that the V3-directed response dominated 
after three immunizations. This is consistent with the notion that the variable regions of 
Env are immunodominant (236) and may act as decoy epitopes to divert B cell 
responses away from conserved neutralizing Ab targets of Env. Thus in paper II, we 
sought to investigate the impact of the V3-directed response and if there is competition 
between B cells recognizing distinct epitope regions of Env. As in paper I, we took 
advantage of the differential B cell ELISpot assay. Our previous results showed that the 
V3-induced response constituted 40-60% of the total Env-specific recall response 
measured after three immunizations. We hypothesized that if competition were in play, 
immunizing mice with an Env immunogen in which the V3 region was 
immunologically silenced would increase B cell responses to other regions of Env. 
Alternatively, if there were no competition between B cells specific for distinct epitope 
regions, the total Env-specific response would be reduced, as the V3-specific fraction 
of the response would be lost.  
To address this, we generated an Env immunogen in which the V3 region was 
masked by the addition of extra N-linked glycans. We employed this strategy instead of 
deleting the V3 regions as that may introduce novel Env epitopes. We referred to the 
V3 shielded trimers as gV3 (glycan-masked V3). The biochemical integrity of gV3 was 
characterized in binding studies to CD4 as well as to well-characterized monoclonal 
Env-specific Abs with known specificities. We found that Abs specific for non-V3 
regions bound the wild type (wt) Env trimers and gV3 in a similar way, while as 
expected, two V3-specific Abs, 447-52D and 39F, failed to bind gV3, thereby 
confirming effective immune shielding of the V3 region.  
We know from results in paper I that a very small proportion of the recall 
response is specific for V3 after two immunizations of wt Env. However, it was still 
interesting to compare the sub-specificities in the recall response of mice that were 
immunized twice with wt Env or gV3 to detect if the lack of V3 could have an effect on 
the outcome of the gp41- and core reactivities that dominate at this time point. 
However, the results indicated that the lack of V3 did not alter the outcome of the recall 
response after two immunizations. Upon three immunizations, as detected in the 
experiments in paper I, wt Env-immunized animals showed a dominating V3-specific 
recall response. Interestingly, when analyzing the gV3-immunized response, we saw a 
significantly lower number of total Env-specific B cells when using gp140-F and 
gp120-F as probes. Furthermore, upon using the gp120-F-Δ3 or the gp120-F-Δ123 
probe, we detected similar numbers of spots between the groups, indicating that the 
reduced B cell response detected with gp140-F and gp120-F was due to the lack of V3 
specific B cells. This data intriguingly suggest that the development of recall responses 
specific for one region of the Env protein does not affect the development of the 
responses towards other sites of the protein. 
Epitopes on Env that are known to be sensitive to bNAbs are poorly recognized 
by the humoral immune system due to partial shielding of conserved determinants of 
Env. One of the first identified Abs showing broad neutralization to Env was 2F5 
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(192). The epitope recognized by this Ab is a linear epitope, ELDKWA, present in the 
MPER of gp41. This epitope was found to be conserved in a significant proportion 
(72%) of screened HIV-1 isolates (194). A number of attempts to re-elicit the 2F5 Ab 
have been undertaken by immunization with different immunogens containing the 
MPER peptide with only weak or no neutralization activity observed (237-241). 
Detailed information about the structure of the ELDKWA peptide is known (154, 239, 
242-244), which has allowed the development of several different scaffold 
immunogens presenting this epitope for more optimal display to the immune system 
(189).   
In paper III, we selected three such epitope scaffolds (ES1, ES2 and ES5) for 
further studies. The immunogens were designed with or without a common MHC class 
II T-helper epitope, PADRE. We first analyzed the immunogenicity of the ES proteins 
following three homologous immunizations of mice using ES1, ES2 or ES5 in 
adjuvant. The presence of 2F5-like Abs in the different groups was assessed by 
analyzing binding to a fourth 2F5 scaffold protein, ES4. The Abs binding to this 
scaffold should be 2F5-specific since this scaffold was not used for immunization in 
any of the groups. We found that 2F5-specific responses elicited with ES1 and ES2 
were very low to non-detectable. In contrast, the ES5 scaffold induced high levels of 
2F5-binding Abs after three homologous immunizations. The specificity of the 
response was confirmed by using free 2F5 peptide to successfully compete out serum 
binding to ES4. Inclusion of the PADRE epitope in the scaffold protein did not enhance 
the 25F-elicited response, probably because the scaffold proteins already included 
potent T-helper epitopes.  
It is likely that when homologous prime-boosting is used, a large proportion of 
the recall response is specific for parts of the scaffold protein other than the introduced 
2F5 epitope. To circumvent this problem, we tested whether a heterologous 
immunization regimen, using different 2F5-presenting scaffolds inoculated in a 
sequential manner, would lead to a more focused 2F5-specific response. We 
immunized mice two weeks apart with the ES5, ES1 and ES2 scaffolds with or without 
the PADRE epitope. Our results show that the 2F5-specific ES5 elicited primary Ab 
response in serum could be boosted by the heterologous epitope ES1. Furthermore, the 
ES2 scaffold, which only induced a very low 2F5-specific response in the homologous 
regimen further boosted the response suggesting that memory B cells formed by 
priming with ES5 effectively recognized the 2F5 epitope on the other scaffold proteins. 
Compared to the homologous regimen, the inclusion of PADRE was more important in 
the heterologous regimen, consistent with the notion that the same helper epitope needs 
to be present when boosting in order to activate the existing memory helper T cells.  
To determine the relative frequency of 2F5-specific ASCs elicited in the 
homologous versus the heterologous immunization regimen we adopted the B cell 
ELISpot assay developed in paper I to detect 2F5 specific B cells. Using this assay, we 
showed that 2F5-specific B cells were only detected in mice immunized in a 
homologous regimen with ES5 or in the heterologous regimen with ES5, ES1 and ES2. 
There were no detectable 2F5-specific B cells in the mice immunized in a homologous 
regimen with ES1 and ES2. This did not depend on the lack of T cell help since only 
scaffolds including PADRE were used. There was no significant difference in the ratio 
of 2F5-specific ASCs induced by the ES5 homologous regimen compared to the 
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heterologous regimen. This suggests that engagement of B cell responses to the other 
parts of the scaffold did not impact the evolution of graft-specific responses. We do not 
yet know why the immunogenicity of the 2F5 epitope in the context of ES5 measured 
both on the plasma and cellular levels, was greater than for the other scaffolds. One 
possibility is that this scaffold is more flexible (189), which has been noted to correlate 
positively with immunogenicity for other Ags (245).  
When Abs from both the homologous and the heterologous regimen were tested 
for neutralization capacity in vitro, no neutralizing activity against selected HIV-1 
isolates was detected. One reason for this could be that in comparison to the scaffold 
induced Abs, the CDR3 loop of the original 2F5 Ab expresses several highly 
hydrophobic amino acids that are thought to form additional contact with the 
membrane of the virus. Currently, novel scaffolds are being produced where this is 
considered. Another reason why the scaffold elicited Ab responses were not 
neutralizing could be that the 2F5 epitope is not presented on the scaffolds in exactly 
the same three-dimensional structure as it is on the native Env trimer.  
In paper IV, we took advantage of the effects of the B cell survival factor BLyS, 
to investigate the hypothesis that there are limitations in the naïve B cell pool that limit 
elicitation of bNAbs. BLyS has been proposed to regulate the homeostasis of self/non-
self BCR reactivities in the naïve B cell pool. We hypothesized that exogenous BLyS 
treatment of naïve mice would alter the naïve B cell repertoire and that this would 
influence the outcome of Env-induced B cell responses compared to control-treated 
mice. Accordingly, we injected naïve mice with 10 µg of BLyS or PBS, once per day, 
for ten consecutive days before they were immunized with Env. To confirm the effects 
of BLyS and determine the kinetics of BLyS-induced effects on the naïve B cells, we 
first sacrificed selected mice for analysis at 1, 5, 9, 13, 17 and 21 days after the last day 
of BLyS treatment without Env immunization.  
Upon analyzing these mice at day one after terminating BLyS-treatment, we 
found the total size of the spleen significantly increased in BLyS-treated mice most 
likely due to increased numbers of B220+ B cells detected. Specifically, it was the 
number of surviving transitional B cells that caused this increase since we could detect 
an increased number of T2 but not T1 cells in BLyS-treated mice compared to control 
mice, which agrees with the literature and shows that BLyS does not affect the output 
of immature B cells from the BM (56). Upon analysis of the mature naïve B cell pools, 
we determined that there were increased levels of both follicular B cells and MZBs 
with a more pronounced effect on the MZBs. This is consistent with the notion that 
MZBs are more sensitive to depletion of BLyS than follicular B cells (53). Because we 
planned to immunize BLyS-treated mice and study the development of the Ag-
experienced B cells, we also wanted to assess the effect of BLyS on the architecture of 
the SLOs as the T and B cell areas were found to be disrupted in mice that were 
transgenic for BLyS (44). However, by immunostaining the white pulp in spleen, we 
demonstrated that the architecture of the B- and T cell areas was intact after ten days of 
BLyS treatment. Analysis of serum levels of Ab reactivities against dsDNA, 
phosphorylcholine (PC) and cardiolipin showed elevated levels of these reactivities in 
BLyS treated mice but when these levels were normalized to total IgM, there were no 
difference between BLyS-treated and controls indicating that there were no specific 
increase in self-reactive Abs. When we analyzed the BLyS-induced effects at later time 
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points after the last day of injection we could see that they were highly transient, and 
already at day five, the numbers of naïve B cells were close to baseline levels.  We 
concluded that subsequent Env immunization should therefore be performed 
immediately after finalized BLyS treatment. 
To analyze the effect of BLyS-treated animals on the outcome of an Env-
immunization, BLyS- and PBS-treated animals were primed with Env and adjuvant one 
day after the last day of treatment. Mice were then boosted once or twice with Env 
trimers with two-weeks intarvals. We hypothesized that if any new Env-specific naïve 
B cells had been generated during the BLyS treatment, these B cells could get recruited 
into the immune response at the priming event and further proliferate with subsequent 
boosting. At four or 21 days after the second Env-immunization we analyzed the 
initiation of the B cell response by determining the level of GC formation by flow 
cytometry. Surprisingly, even though the total number of naïve B cells available at the 
priming event was increased in the BLyS-treated animals, we detected no difference in 
the total number of GC-cells. There were also no difference between BLyS- and control 
treated groups when we used the optimized B cell ELISpot to enumerate the total 
number of Env-specific ASCs in spleen at day four after second immunization, the 
Env-specific PC in BM at day 21 after second immunization or when we analyzed the 
presence of Env-specific memory B cells in the spleen after in vitro stimulation. Also, 
we could not detect any difference when we analyzed the total Env-binding Abs in sera 
by ELISA after two or three immunizations. We hypothesized that this could be due to 
further regulation of the total number of cells that can enter the GC. For example, it is 
possible that there is limited space or limitations in T cell help or the amount of Ag 
thereby restricting the formations of larger GCs.  
In addition, we investigated whether the quality of the Env-specific B cells were 
different in BLyS and control-treated mice using the optimized differential Env-specific 
B cell ELISpot described in paper I. These analyses showed no consistent difference in 
the sub-specificities in the BLyS and control-treated mice. We further analyzed the 
quality of the serum Abs by determining their ability to neutralize selected strains of 
HIV-1 pseudoviruses in vitro. In brief, the neutralization assay is based on the infection 
by pseudo-HIV-1 viruses of reporter target cells, a well-validated assay in the HIV-1 
neutralizing Ab field (191).  Using this assay for analysis of the serum after two 
immunizations with Env trimers, we detected neutralizing activity above background in 
four out of twelve BLyS-treated mice compared to zero out of twelve in the control 
group. When this experiment was repeated using BLyS and control-treated mice 
immunized three times with Env trimers, we detected neutralization activity in both the 
BLyS- and the control-treated mice, but with significantly more responders in the 
BLyS-treated group. A third experiment of mice immunized four times with a longer 
timeframe, 60 days, between the third and the fourth immunization, gave the similar 
result.  
BLyS has been proposed to have an effect on the selection of the naïve B cell 
repertoire by affecting the survival of transitional B cells (40, 63). It is thus tempting to 
speculate that the increased neutralizing activity we observed in the BLyS-treated 
animals is due to an altered naïve B cell repertoire, which led to the engagement of 
novel B cell reactivities into the Env-specific B cell response. It is also possible that the 
effect we detected was due to modulations by BLyS on the GC since it has been 
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suggested that BLyS has an effect on the duration of the GC response (246). However, 
since we only administered BLyS prior to the first Env immunization and the effect of 
BLyS treatment was short-lived we consider this possibility less likely. For a more 
complete understanding of how BLyS treatment induced these downstream effects, a 
more detailed analysis of the naïve B cell repertoire in BLyS and control treated non-
immunized and Env-immunized animals is needed. 
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7 CONCLUDING REMARKS 
Throughout the work presented in this thesis, we used the well-characterized, 
recombinant, soluble HIV-1 Env trimer as a model immunogen to study basic B cell 
questions relevant to vaccine development. The primary advantage of this approach is 
the obvious clinical relevance of Env compared to model Ags more commonly used in 
the basic B cell biology field such as NP, OVA and SRBC. A potential disadvantage of 
using HIV-1 Env as a model Ag is that it is a highly complex protein Ag, which may 
not be representative of smaller, less glycosylated or unglycosylated Ags. Nevertheless, 
we believe a more thorough and basic understanding of how organisms respond to 
relevant vaccine Ags is needed and this requires studies that bridge the fields of basic B 
cell biology and vaccine research.  
The results in paper I confirm that different epitopes on a protein are not equally 
immunogenic and also show that the level of immunogenicity for a specific epitope is 
not static. Rather, epitope recognition seems to vary over time and with the number of 
times the immune system is challenged with the Ag. In many circumstances, low 
immunogenicity can probably be explained by steric hindrance and occlusion of the 
epitope. In these cases, approaches such as scaffold design may be helpful tools to 
increase immunogenicity of a specific epitope as was characterized in paper III. Yet, is 
it also possible that some epitopes are less immunogenic because there are other 
surrounding epitopes that are better at activating the immune response? The findings in 
paper II suggest that this is not the case but rather that there are undefined intrinsic 
regulatory features of individual epitopes. In a way, the results in paper III also 
confirm these results since we do not see increased responses to common epitopes 
using heterologous scaffolds upon immunization. Interestingly, in paper IV our results 
suggest a possibility for the naïve B cell repertoire to be a limiting factor for the Ab 
response to certain epitopes. As has been speculated elsewhere (210), it is possible that 
some plasticity in the naïve B cell repertoire is allowed in order to maintain a fine 
balance between recognizing self and foreign Ags by mechanisms such as those 
controlled by BLyS signaling.  
In conclusion, the results presented in this thesis demonstrate how the B cell 
response evolves following recognition of a clinically relevant viral Ag. These results 
may be become important in the development of future subunit-based vaccines. 
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